These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22574676)

  • 21. Acamprosate campral for alcoholism.
    Med Lett Drugs Ther; 2005 Jan; 47(1199):1-3. PubMed ID: 15599336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The state of pharmacotherapy for the treatment of alcohol dependence.
    Garbutt JC
    J Subst Abuse Treat; 2009 Jan; 36(1):S15-23; quiz S24-5. PubMed ID: 19062347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical and clinical pharmacology of alcohol dependence.
    Tambour S; Quertemont E
    Fundam Clin Pharmacol; 2007 Feb; 21(1):9-28. PubMed ID: 17227441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug adjuncts for treating alcohol dependence.
    Collins GB; McAllister MS; Adury K
    Cleve Clin J Med; 2006 Jul; 73(7):641-4, 647-8, 650-1, passim. PubMed ID: 16845975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isoflavonoid compounds extracted from Pueraria lobata suppress alcohol preference in a pharmacogenetic rat model of alcoholism.
    Lin RC; Guthrie S; Xie CY; Mai K; Lee DY; Lumeng L; Li TK
    Alcohol Clin Exp Res; 1996 Jun; 20(4):659-63. PubMed ID: 8800381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological control of alcohol consumption: tactics for the identification and testing of new drugs.
    Naranjo CA; Cappell H; Sellers EM
    Addict Behav; 1981; 6(3):261-9. PubMed ID: 7027758
    [No Abstract]   [Full Text] [Related]  

  • 27. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.
    Mason BJ; Heyser CJ
    Expert Opin Drug Saf; 2010 Jan; 9(1):177-88. PubMed ID: 20021295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy.
    Kiefer F; Mann K
    Curr Pharm Des; 2010; 16(19):2098-102. PubMed ID: 20482510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel non-imidazole histamine H3 receptor antagonist DL77 reduces voluntary alcohol intake and ethanol-induced conditioned place preference in mice.
    Bahi A; Sadek B; Nurulain SM; Łażewska D; Kieć-Kononowicz K
    Physiol Behav; 2015 Nov; 151():189-97. PubMed ID: 26169446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence.
    Mason BJ; Heyser CJ
    CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):23-32. PubMed ID: 20201812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of molecular targets associated with ethanol toxicity and implications in drug development.
    Wang LL; Yang AK; He SM; Liang J; Zhou ZW; Li Y; Zhou SF
    Curr Pharm Des; 2010; 16(11):1313-55. PubMed ID: 20184550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research.
    Kranzler HR
    Alcohol Alcohol; 2000; 35(6):537-47. PubMed ID: 11093959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The pharmacologic treatment of the alcohol dependence].
    Castro LA; Baltieri DA
    Braz J Psychiatry; 2004 May; 26 Suppl 1():S43-6. PubMed ID: 15729444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyamine modulation of NMDARs as a mechanism to reduce effects of alcohol dependence.
    Barron S; Lewis B; Wellmann K; Carter M; Farook J; Ring J; Rogers DT; Holley R; Crooks P; Littleton J
    Recent Pat CNS Drug Discov; 2012 Aug; 7(2):129-44. PubMed ID: 22574674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
    Mann K; Kiefer F; Smolka M; Gann H; Wellek S; Heinz A;
    Alcohol Clin Exp Res; 2009 Apr; 33(4):674-83. PubMed ID: 19170666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy for alcohol dependence: status of current treatments.
    Franck J; Jayaram-Lindström N
    Curr Opin Neurobiol; 2013 Aug; 23(4):692-9. PubMed ID: 23810221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
    Johnson BA; Ait-Daoud N
    Psychopharmacology (Berl); 2000 May; 149(4):327-44. PubMed ID: 10867960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
    Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
    Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence.
    Scott LJ; Figgitt DP; Keam SJ; Waugh J
    CNS Drugs; 2005; 19(5):445-64. PubMed ID: 15907154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.
    Littleton J; Zieglgänsberger W
    Am J Addict; 2003; 12(s1):s3-s11. PubMed ID: 14972776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.